Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Unity Biotechnology, Inc. (UBX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., August 8, 2023 --"
05/09/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., May 9, 2023 --"
03/15/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 15, 2023 --"
11/08/2022 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates - Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Phase 2 ENVISION Study in wet Age-Related Macular Degeneration Expected in First Quarter of 2023 - - As of September 30, 2022, UNITY had approximately $103.9 million in cash, cash equivalents and marketable securities, providing runway into the first quarter of 2024 - SOUTH SAN FRANCISCO, Calif., November 8, 2022 --"
08/12/2022 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates"
05/10/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates"
11/10/2021 8-K Quarterly results
Docs: "UBX1325 Phase 2 study in DME currently enrolling, with additional Phase 2 study in AMD planned for 1H22 - UNITY to present at invitation-only Eyecelerator innovation conference at AAO"
08/10/2021 8-K Quarterly results
Docs: "UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema and wet age-related macular degeneration - Results from Phase 1study of UBX1325 in additional patients with wet AMD expected by end of year - UBX1325 Phase 2a proof-of-concept study enrolling patients with DME; data expected first half of 2022"
05/11/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates"
07/31/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates"
03/11/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Third Quarter 2019 Financial Results and Business Updates"
08/07/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results"
03/06/2019 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Program Updates"
08/09/2018 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Second Quarter 2018 Financial Results"
06/07/2018 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports First Quarter 2018 Financial Results SAN FRANCISCO, Calif., June 7, 2018 — UNITY Biotechnology, Inc. , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported first quarter 2018 financial results. As of March 31, 2018, UNITY had cash, cash equivalents and short-term investments of $134.6 million. This amount excludes $5.0 million of proceeds from the final closing of UNITY's $60 million Series C convertible preferred stock financing in April 2018, and $79.1 million of proceeds after underwriting discounts and commission from UNITY's initial public offering completed in May 2018. “We had a very productive start to 2018. In addition to completing key financing milestones, we file..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy